Core Insights - Calidi Biotherapeutics Inc. has appointed Dr. Guy Travis Clifton as Chief Medical Officer, Consultant, and Advisor, which is expected to enhance the company's capabilities in advancing its oncology programs [1][2][3] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies, utilizing proprietary stem cell-based platforms and enveloped viruses to treat various oncology indications, including high-grade gliomas and solid tumors [4] - The company aims to protect and amplify oncolytic viruses to improve efficacy and patient safety, with a dual approach that may treat or prevent metastatic disease [4] Leadership and Expertise - Dr. Clifton brings over 17 years of experience in drug development, early-phase clinical trials, and cancer immunotherapy, having served as a surgical oncologist in the US Army and co-founder of Parthenon Therapeutics [2][3] - His extensive advisory experience with over 20 companies and more than 80 peer-reviewed publications in cancer-related topics will be instrumental in guiding Calidi's clinical strategies [2][3] Clinical Development - Calidi has recently filed an Investigational New Drug (IND) application for a dose escalation trial of its product CLD-201 in adult patients with solid tumors, indicating progress in its clinical development pipeline [2] - The company's innovative platforms are designed to target metastatic tumor cells and solid tumors, potentially transforming cancer treatment methodologies [3]
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor